基于“邪伏肠络”理论探讨结直肠“炎癌转化”的动态演变机制及治疗思路

刘运泽; 郑浩呈; 李园; 丁霞

doi:10.3969/j.issn.1006-2157.2024.10.002

您当前的位置：

首页 >

文章列表页 >

基于“邪伏肠络”理论探讨结直肠“炎癌转化”的动态演变机制及治疗思路

“中医药防治‘炎癌转化’”专题 | 更新时间：2024-10-29

- 基于“邪伏肠络”理论探讨结直肠“炎癌转化”的动态演变机制及治疗思路
- Dynamic evolution mechanism and treatment ideas of colorectal " inflammation-mediated carcinogenesis" based on the " latent pathogens trapped in the intestinal collaterals" theory
- 北京中医药大学学报 2024年47卷第10期页码：1343-1348
- 作者机构：
  
  1.北京中医药大学东直门医院　北京　100700
  2.北京中医药大学体质学院
  3.北京中医药大学中医学院
- 作者简介：
  
  刘运泽，男，在读博士生
  #丁霞，女，博士，教授，博士生导师，主要研究方向：中西医结合防治消化系统疾病的基础与临床研究，E-mail：dingx@bucm.edu.cn
- 基金信息：
  
  国家自然科学基金面上项目(82374292);北京中医药大学校级科研纵向发展基金(2021-ZXFZJJ-035)
- DOI：10.3969/j.issn.1006-2157.2024.10.002
  中图分类号： R259
- 纸质出版日期：2024-10-30，
  
  网络出版日期：2024-10-08，
  
  收稿日期：2024-04-07，
- 稿件说明：
移动端阅览
刘运泽, 郑浩呈, 李园, 等. 基于“邪伏肠络”理论探讨结直肠“炎癌转化”的动态演变机制及治疗思路[J]. 北京中医药大学学报, 2024,47(10):1343-1348.

LIU Yunze, ZHENG Haocheng, LI Yuan, et al. Dynamic evolution mechanism and treatment ideas of colorectal " inflammation-mediated carcinogenesis" based on the " latent pathogens trapped in the intestinal collaterals" theory[J]. Journal of Beijing University of Traditional Chinese Medicine, 2024,47(10):1343-1348.
刘运泽, 郑浩呈, 李园, 等. 基于“邪伏肠络”理论探讨结直肠“炎癌转化”的动态演变机制及治疗思路[J]. 北京中医药大学学报, 2024,47(10):1343-1348. DOI： 10.3969/j.issn.1006-2157.2024.10.002.

LIU Yunze, ZHENG Haocheng, LI Yuan, et al. Dynamic evolution mechanism and treatment ideas of colorectal " inflammation-mediated carcinogenesis" based on the " latent pathogens trapped in the intestinal collaterals" theory[J]. Journal of Beijing University of Traditional Chinese Medicine, 2024,47(10):1343-1348. DOI： 10.3969/j.issn.1006-2157.2024.10.002.

摘要

结直肠炎症患者罹患结直肠癌的风险较普通人群明显升高。迁延日久的炎症是诱发结直肠癌变的重要因素，结直肠炎症→异型增生→结直肠癌是常见的结直肠“炎癌转化”的动态病理演变过程。中医学对于结直肠“炎癌转化”的病机尚缺乏系统共识，本文提出“邪伏肠络”理论，用以阐释结直肠“炎癌转化”动态演变过程中的病机发展规律，邪气伏藏于肠络而正气无法驱邪外出，待内外因素触发，伏邪内动，损伤肠道组织；病程迁延使得正气愈衰，邪气伏藏于肠络，与痰湿、瘀血互结，加速形成积聚，最终导致癌变。“邪伏肠络”是贯穿结直肠“炎癌转化”全过程的核心病机，应以透邪通络为治疗原则，透达伏邪，扶助正气，通畅肠络，从而截断“炎癌转化”进程。阐释“邪伏肠络”理论有助于完善结直肠“炎癌转化”的辨证论治体系，为临床治疗本病提供新思路。

Abstract

The risk of colorectal cancer is substantially higher in patients with long-term colorectal inflammation than in the general population. Prolonged inflammation is an essential factor that triggers colorectal cancer. The dynamic pathological evolution process of the classic " inflammation-mediated carcinogenesis" in the colorectum is proctocolitis→dysplasia→cancer. Traditional Chinese medicine lacks a systematic consensus on the pathogenesis of colorectal " inflammation-mediated carcinogenesis". This article proposes the theory of " pathogenic factors lurk intestinal collaterals" to explain the development law of pathogenesis in the dynamic evolution of colorectal " inflammation-mediated carcinogenesis". Internal and external factors can trigger the movement of the latent pathogenic factors

thereby damaging the intestinal tissues

when latent pathogenic factors are hidden in the intestinal collaterals

and the healthy qi is unable to expel them. The prolonged course of the disease further weakens the healthy qi

allowing the latent pathogenic factors to accumulate in the intestinal collaterals

intertwine with phlegm-dampness and blood stasis

accelerate accumulation

and lead to cancer. " Latent pathogens trapped in the intestinal collaterals" is the core pathogenesis during inflammation-mediated carcinogenesis. Thus

to prevent colorectal inflammation-mediated carcinogenesis

consideration should be given to the principle of driving away pathogenic factors and dredging the collaterals in clinical practice. The theory regarding " latent pathogens trapped in the intestinal collaterals" can provide a theoretical reference for syndrome differentiation and treating colorectal inflammation-mediated carcinogenesis and offer novel ideas for clinical treatment.

关键词

结直肠炎癌转化邪伏肠络肠络透邪通络

Keywords

colorectuminflammation-mediated carcinogenesislatent pathogens trapped in the intestinal collateralsintestinal collateralsdriving away pathogenic factors and dredging the collaterals

references

AI LY, REN YM, ZHU MM, et al. Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis[J]. Gut, 2021, 70(12): 2261-2272.

CHEN HD, LU B, DAI M. Colorectal cancer screening in China: status, challenges, and prospects-China [J]. China CDC Wkly, 2022, 4(15): 322-328.

SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.

SHAH SC, ITZKOWITZ SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management[J]. Gastroenterology, 2022, 162(3): 715-730.

PORTER RJ, ARENDS MJ, CHURCHHOUSE AMD, et al. Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines[J]. J Crohns Colitis, 2021, 15(12): 2131-2141.

RAMOS GP, PAPADAKIS KA. Mechanisms of disease: inflammatory bowel diseases[J]. Mayo Clin Proc, 2019, 94(1): 155-165.

MASI A, FORTINI P, KROKIDIS MG, et al. Increased levels of 5′，8-Cyclopurine DNA lesions in inflammatory bowel diseases[J]. Redox Biol, 2020, 34: 101562.

KALLA R, ADAMS AT, NOWAK JK, et al. Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic and immune-inflammatory influences on the circulating methylome[J]. J Crohns Colitis, 2023, 17(2): 170-184.

CAI J, SUN L, GONZALEZ FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis[J]. Cell Host Microbe, 2022, 30(3): 289-300.

KONG L, POKATAYEV V, LEFKOVITH A, et al. The landscape of immune dysregulation in Crohn’s disease revealed through single-cell transcriptomic profiling in the ileum and colon[J]. Immunity, 2023, 56(12): 2855.

SAEZ A, HERRERO-FERNANDEZ B, GOMEZ-BRIS R, et al. Pathophysiology of inflammatory bowel disease: innate immune system[J]. Int J Mol Sci, 2023, 24(2): 1526.

王方园，杨玉莹，王栋，等. 基于“虚、瘀、毒”理论探讨结直肠炎-癌转化机制[J]. 吉林中医药，2023, 43(1): 18-23.

杨頔. 基于《黄帝内经》的伏气温病理论研究[D]. 兰州：甘肃中医药大学，2022.

董南希，蔡丹莉，毛威，等. 浅谈《黄帝内经》伏邪之说与温病治法[J]. 浙江中医杂志，2018, 53(10): 712-713.

南京中医药大学. 伤寒论译释[M]. 上海：上海科学技术出版社，2023: 222.

刘吉人. 伏邪新书[M]//曹炳章. 中国医学大成(十六). 上海：上海科学技术出版社，1990: 203.

李坤宁，张庆祥，徐成岩，等. 伏邪病因病机特点的探析[J]. 中国中医急症，2019, 28(12): 2170-2173.

南京中医学院，校释. 诸病源候论校释(上册) [M]. 北京：人民卫生出版社，1982: 698.

刘峰，刘林，王垂杰. 溃疡性结肠炎病因病机及治疗进展[J]. 山东中医药大学学报，2021, 45(1): 143-147.

程婷，杨文明. 伏邪学说理论探析[J]. 辽宁中医药大学学报，2017, 19(12): 86-89.

JANS D, CLEYNEN I. The genetics of non-monogenic IBD[J]. Hum Genet, 2023, 142(5): 669-682.

崔冰慧，郑旭锐. 叶天士“久病入络”学术思想及络治法探析[J]. 中医学报，2020, 35(1): 59-62.

胡勇，邢玉瑞. 基于络病学毒损肠络论治溃疡性结肠炎[J]. 中国中医基础医学杂志，2018, 24(3): 415-417.

常成成，魏聪，吴以岭. 脉络学说“孙络-微血管”概念及其临床指导意义[J]. 中医杂志，2016, 57(1): 7-11.

吴以岭. “脉络-血管系统”相关性探讨[J]. 中医杂志，2007, 48(1): 5-8.

李岩，赵雁，黄启福，等. 中医络病的现代认识[J]. 北京中医药大学学报，2002, 25(3): 1-5.

舒惠荃，王宝山，刘志勇，等. 正邪交争与炎性反应[J]. 现代中西医结合杂志，2006, (16): 2157-2158.

许异川，陆星瑶，单静怡，等. 基于“伏温”探讨“透邪扶正”法治疗活动期溃疡性结肠炎[J]. 时珍国医国药，2023, 34(12): 2977-2980.

严小军，左铮云. 中医对结肠癌前病变机理的探讨[J]. 辽宁中医杂志，2007, 34(7): 905-906.

伍晓涵. 溃疡性结肠炎最新发病机制的认识[J]. 中国中西医结合消化杂志，2023, 31(4): 237-242.

赵明芬，安冬青，汪建萍. 试论伏邪理论的源流及发展[J]. 中医杂志，2016, 57(3): 189-192.

郭星，田云，王延秋. 杜晓泉运用湿热伏邪理论辨治溃疡性结肠炎临床经验[J]. 江苏中医药，2020, 52(8): 24-27.

CHOI W T, SALOMAO M, ZHAO L, et al. Hypermucinous, goblet cell-deficient and crypt cell dysplasias in inflammatory bowel disease are often associated with flat/invisible endoscopic appearance and advanced neoplasia on follow-up[J]. J Crohns Colitis, 2022, 16(1): 98-108.

周燕芳，王桧，宋艳丽，等. 基于“伏邪阻络，络息成积”探析子宫肌瘤的中医病机[J]. 环球中医药，2023, 16(12): 2508-2511.

杨士瀛. 仁斋直指方论[M]. 盛维忠，校注．福州：福建科学技术出版社，1989: 579.

姚鹏宇，程广清. 叶天士《临证指南医案》伏邪理论探析[J]. 中国中医基础医学杂志，2021, 27(2): 225-227.

梁沛崧，黄辉. 叶天士与柳宝诒伏温思想的异同比较[J]. 中医药导报，2023, 29(3): 198-201.

张慧，张云松，姜璐，等. 以“络以通为用”为指导探讨溃疡性结肠炎的诊疗[J]. 北京中医药大学学报，2021, 44(11): 1044-1048.

高世栻. 医学真传[M]. 王新华，点注．南京：江苏科学技术出版社，1983: 32.

张兰坤，过伟峰，肖婧，等. 从叶天士“络以通为用”学说谈通络药物的临床应用[J]. 中医杂志，2014, 55(9): 804-805.

雷露，吕沛然，张宁，等. 中医治疗炎症性肠病机制的研究进展[J]. 中医药学报，2024, 52(2): 116-121.

WEI XN, LENG XH, LI GY, et al. Advances in research on the effectiveness and mechanism of traditional Chinese medicine formulas for colitis-associated colorectal cancer[J]. Front Pharmacol, 2023, 14: 1120672.

YANG YW, LIU ZH, LYU HB, et al. Traditional Chinese medicine-induced treatment in colitis-associated colorectal cancer[J]. Chin Med J, 2023, 136(10): 1249-1250.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据